By CRISIL
Venus Remedies announced that the company had availed a major part of the term loans for its on going research and development activities. The company has been consequently awarded with European and other regulated geographies "GMP" certifications for its manufacturing plants. These unstinted efforts have resulted in the company having more than 100 patents globally, besides a steady pipeline of products by Venus Medicine Research Centre. The Commercial outcome of these Initiatives is that the company has been able to make prestigious International Tie ups for its research products with some of the best pharmaceutical companies of the world. Negotiations are also continuing for out licensing at advanced stages to some block buster products. The gestation period for the research and its commercialization is long as compared to the period for normal business activities.The Company made the announcement in reference to the downgrading of external rating by CRISIL.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app